Outpatient COVID-19 Treatment Referral Process

Based on feedback from our providers, Kettering Health will begin a new ordering and referral process for outpatient COVID treatments on Monday January 24, 2022. The goal of this new process is to ensure high-risk COVID outpatients receive the best available treatment based on National Institute of Health recommendations, inventory, and patient-specific factors.

Please see attachment for full referral process and considerations for pregnant and pediatric patients.

All treatment options (oral and intravenous infusions) will have the same criteria for use as approved by the Kettering Health Pharmacy and Therapeutics Committee:

Patient must meet ALL of the following criteria:
 Positive test for SARS-CoV-2
 Onset of symptoms within the past 7 days
 Patient is 18 years of age or older
 Patient does not require supplemental oxygen or there is no increase in baseline oxygen needs


One (1) of the following:
 Pregnancy
 Patients ≥ 65 years old and not fully vaccinated per CDC definition
 Within 1 year of receiving B-cell depleting therapy (riTUXimab, ocrelizumab, ofatumumab, ibritumomab tiuxetan, obinutuzumab, belimumab)
 Receiving ibrutinib, acalabrutinib, or zanubrutinib therapy
 Chimeric antigen receptor T-cell recipients (CAR T-Cell Therapy) (Idecabtagene Vicleucel, Brexucabtagene Autoleucel, Axicabtagene Ciloleucel, Axicabtagene Ciloleucel)
 Hematopoietic cell transplant recipients
 Graft-versus-host disease
 Hematological malignancy on active therapy
 Solid organ transplant recipients
 HIV Patients with CD4 count < 50 cells/mm3

January 22, 2022